Maxcyte, Inc. revenue
Maxcyte, Inc.'s revenue was $33.0m in fiscal 2025, down 14.5% on the year before. Since fiscal 2019 ($21.6m) it has grown at a compound 7.3% a year. Over the last twelve months it was $31.1m.
Revenue history
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22 | 26 | 34 | 44 | 41 | 39 | 33 | 31 |
| Growth on the year before | — | +21.0% | +29.5% | +30.6% | −6.7% | −6.4% | −14.5% | — |
| Gross profit | 19 | 23 | 30 | 39 | 37 | 32 | 27 | 25 |
| Gross margin | 88.4% | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% | 79.2% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $18.7M | ▼ 11.4% |
| Assay and Other Service Revenue | $2M | — |
| Licenses | $300,000 | ▼ 98.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $21.1M | 63.8% | ▼ 18.2% |
| Outside the US | $11.9M | 36.2% | ▼ 7.1% |
From Maxcyte, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Maxcyte, Inc. | $31.1m | -13.2% | -8.6% |
| Bionano Genomics, Inc. | $30.2m | 10.0% | -1.4% |
| Rapid Micro Biosystems, Inc. | $35.2m | 16.1% | 22.5% |
| Omniab, Inc. | $40.2m | 90.6% | -14.7% |
| Alpha Teknova, Inc. | $43.7m | 12.3% | 3.7% |
| Champions Oncology, Inc. | $60.7m | 6.7% | 4.8% |
Compare with peers
- Bionano Genomics, Inc. revenue
- Rapid Micro Biosystems, Inc. revenue
- Omniab, Inc. revenue
- Alpha Teknova, Inc. revenue
- Champions Oncology, Inc. revenue
Head to head: BNGO vs MXCTMXCT vs RPIDMXCT vs OABI
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies